Choong-wae's itraconazole wins COS certification

Published: 2004-10-28 06:57:00

Updated: 2004-10-28 06:57:00

Choong-wae said on October 24 that its itraconazole has acquired a COS (Certification of Suitability of Monographs of the European Pharmacopoeia) certification from the European Directorate for the Quality Medicines, following the initial COS acquisition on ketoconzole in 2002.

The company is ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK